UBS Group Lowers Pfizer (NYSE:PFE) to Neutral
UBS Group Lowers Pfizer (NYSE:PFE) to Neutral
UBS Group lowered shares of Pfizer (NYSE:PFE – Get Rating) from a buy rating to a neutral rating in a research note published on Thursday, MarketBeat reports. They currently have $47.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $55.00.
据MarketBeat报道，在周四发布的一份研究报告中，瑞银集团将辉瑞(NYSE：PFE-GET评级)的股票评级从买入下调至中性。他们目前对这家生物制药公司的股票设定了47.00美元的目标价，低于之前55.00美元的目标价。
Several other equities research analysts have also recently commented on the company. Bank of America cut Pfizer from a buy rating to a neutral rating and set a $60.00 target price on the stock. in a research note on Wednesday, January 4th. JPMorgan Chase & Co. set a $50.00 target price on Pfizer in a research note on Wednesday, January 18th. Barclays upped their price objective on Pfizer from $44.00 to $49.00 and gave the stock an equal weight rating in a research note on Wednesday, November 2nd. SVB Leerink upped their price objective on Pfizer from $48.00 to $49.00 and gave the stock a market perform rating in a research note on Thursday, November 3rd. Finally, StockNews.com initiated coverage on Pfizer in a research note on Wednesday, October 12th. They set a strong-buy rating on the stock. Seven analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $52.33.
其他几位股票研究分析师最近也对该公司发表了评论。美国银行将辉瑞的评级从买入下调至中性，并为该股设定了60.00美元的目标价。在1月4日星期三的一份研究报告中。摩根大通(JPMorgan Chase&Co.)在1月18日周三的一份研究报告中为辉瑞设定了50美元的目标价。11月2日周三，巴克莱在一份研究报告中将辉瑞的目标价从44.00美元上调至49.00美元，并给予该股同等权重的评级。11月3日，SVB Leerink在一份研究报告中将辉瑞的目标价从48.00美元上调至49.00美元，并给出了该股的市场表现评级。最后，StockNews.com在10月12日星期三的一份研究报告中开始了对辉瑞的报道。他们对该股设定了强力买入评级。七位分析师对该股的评级为持有，两位分析师给出了买入评级，一位分析师对该公司股票发出了强烈的买入评级。根据MarketBeat.com的数据，该股目前的平均评级为持有，共识目标价为52.33美元。
Pfizer Trading Down 1.0 %
辉瑞股价下跌1.0%
NYSE:PFE opened at $43.79 on Thursday. Pfizer has a fifty-two week low of $41.44 and a fifty-two week high of $56.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.37. The stock has a market capitalization of $245.81 billion, a PE ratio of 8.42, a price-to-earnings-growth ratio of 1.09 and a beta of 0.67. The business's 50-day simple moving average is $49.45 and its 200-day simple moving average is $47.95.
纽约证交所：PFE周四开盘报43.79美元。辉瑞在52周低点为41.44美元，在52周高点为56.32美元。该公司的债务权益比为0.35，流动比率为1.59，速动比率为1.37。该股市值为2,458.1亿美元，市盈率为8.42，市盈率为1.09，贝塔系数为0.67。该业务的50日简单移动均线切入位在49.45美元，200日简单移动均线切入位在47.95美元。
Pfizer Increases Dividend
辉瑞增加股息
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Investors of record on Friday, January 27th will be paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, January 26th. This is a boost from Pfizer's previous quarterly dividend of $0.40. Pfizer's dividend payout ratio is 31.54%.
该公司最近还宣布了季度股息，将于3月3日星期五支付。1月27日(星期五)登记在册的投资者将获得0.41美元的股息。这意味着年化股息为1.64美元，收益率为3.75%。本次股息除息日为1月26日(星期四)。这比辉瑞之前的季度派息0.40美元有所提振。辉瑞的派息比率为31.54%。
Institutional Inflows and Outflows
机构资金流入和流出
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. RB Capital Management LLC grew its holdings in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock valued at $282,000 after buying an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. grew its holdings in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank grew its holdings in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. Ergoteles LLC grew its holdings in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock worth $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock worth $69,238,000 after purchasing an additional 79,887 shares in the last quarter. 67.62% of the stock is owned by institutional investors and hedge funds.
一些机构投资者和对冲基金最近增持或减持了PFE的股份。RB Capital Management LLC在第一季度增持辉瑞6.7%的股份。RB Capital Management LLC现在持有这家生物制药公司5,446股股票，价值28.2万美元，上个季度又购买了341股。铁木财富管理有限责任公司。第一季度辉瑞的持有量增加了1.1%。铁木财富管理有限责任公司。现在拥有36,081股这家生物制药公司的股票，价值1,868,000美元，在上个季度又购买了400股。联合银行在第一季度增持了0.6%的辉瑞股票。联合银行现在拥有46,671股这家生物制药公司的股票，价值2,416,000美元，上个季度又购买了290股。第一季度，Ergoeles LLC对辉瑞股票的持有量增加了136.3%。在上个季度增持了21,209股后，Ergoeles LLC现在拥有36,766股这家生物制药公司的股票，价值1,903,000美元。最后，麦肯锡金融公司在第一季度增持了6.4%的辉瑞股票。麦肯锡金融公司(Mackenzie Financial Corp)目前持有这家生物制药公司1,337,418股股票，价值69,238,000美元，此前该公司在上个季度又购买了79,887股票。67.62%的股票由机构投资者和对冲基金持有。
Pfizer Company Profile
辉瑞公司简介
(Get Rating)
(获取评级)
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
辉瑞是一家以研究为基础的全球生物制药公司。它在全球范围内从事生物制药产品的发现、开发、制造、营销、销售和分销。该公司在发达和新兴市场开展合作，推动健康、预防、治疗和治疗，挑战最令人畏惧的疾病。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取StockNews.com关于辉瑞的研究报告
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受辉瑞日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对辉瑞及相关公司评级的每日简明摘要。